Novavax Goes Through the Change as it Sheds Estrogen Drug to Focus on Vaccine Production

SUGAR LAND--May 2, 2008--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--What a difference a day makes, or in the case of Novavax Incorporated (NASDAQ:NVAX) (Rockville, Maryland), just a few short years. Not long ago, the pharma company's sole product was estrogen-replacement therapy Estrasorb, and it was struggling as it was buried under a $35 million debt with only $5 million in cash and burning $2 million per month. Today, the company is flush with capital, some invested by its new partner GE Healthcare, a division of General Electric (NYSE:GE) (Fairfield, Connecticut) as it completes a shift in therapeutic focus to vaccine development and production.